Pfizer acquired Global Blood Therapeutics for approximately $5.4 billion ($68.50 per share in cash), gaining Oxbryta (voxelotor), a first-in-class HbS polymerization inhibitor approved for sickle cell disease, along with inclacumab (Phase III) and GBT601 pipeline assets.